## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s) : Pedro Cuevas Sanchez, et al.

Application No. : 10/588,166

Filing Date : February 16, 2005

Title of Invention : USE OF 2.5-DIHYDROXYBENZENESULPHONIC ACID IN

THE PRODUCTION OF MEDICAMENTS FOR THE

TREATMENT OF ANGIODEPENDENT DISEASES SUCH AS

CANCER AND PSORIASIS

Confirmation No. : 5152

Examiner : Anna Pagonakis

Group Art Unit : 1628

FILED VIA EFS-Web 745 Fifth Avenue on January 5, 2011 New York, NY 10151

## SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

The Examiner's attention is respectfully directed to the following documents set forth in the accompanying form SB/08a. A copy of the cited documents are enclosed.

Applicants request that the Examiner consider and make of record the documents cited herein and that a copy of the form SB/08a, initialed by the Examiner, is returned to Applicants' attorneys. A copy of the Spanish language version of the attached Acnisdin and Acnisdin Retinoico references was previously cited in the Information Disclosure Statement filed on July 27, 2010. We now have English translations available and are submitting them accordingly.

This Information Disclosure Statement is not a representation that the documents cited

Page 1 00828079.DOC

herein are considered most pertinent, or that a search has been undertaken, or that the cited documents are indeed prior art. The Examiner is invited to undertake an independent search.

No fee is deemed necessary, since this Information Disclosure Statement is being filed after receipt of the Notice of Allowance mailed October 7, 2010 and is submitted concurrently with Applicants' Request for Continued Examination. If, however a fee is deemed necessary for this submission, the Commissioner is authorized to charge any such required fees to Deposit Account 50-0320.

Respectfully submitted,

FROMMER LAWRENCE & HAUG LLP

By:

Sandra Kuzmich Reg. No. 46,117

Kathleen N. Ehrhard Reg. No. 55,144

Tel. No. (212) 588-0800 Fax No. (212) 588-0500

Page 2 00828079.DOC